Rani Therapeutics Holdings Inc [NASDAQ: RANI] price surged by 248.27 percent to reach at $1.17.
A sum of 484871028 shares traded at recent session while its average daily volume was at 624.18K shares. Rani Therapeutics Holdings Inc shares reached a high of $2.39 and dropped to a low of $1.13 until finishing in the latest session at $1.64.
The one-year RANI stock forecast points to a potential upside of 80.71. The average equity rating for RANI stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Rani Therapeutics Holdings Inc [RANI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RANI shares is $8.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RANI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Rani Therapeutics Holdings Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 02, 2024. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on June 14, 2024, representing the official price target for Rani Therapeutics Holdings Inc stock. Previously, the target price had yet another raise to $10, while Rodman & Renshaw analysts kept a Buy rating on RANI stock.
RANI Stock Performance Analysis:
Rani Therapeutics Holdings Inc [RANI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 257.92. With this latest performance, RANI shares gained by 240.53% in over the last four-week period, additionally plugging by 40.17% over the last 6 months – not to mention a rise of 19.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RANI stock in for the last two-week period is set at 92.99, with the RSI for the last a single of trading hit 0.2384, and the three-weeks RSI is set at 0.1274 for Rani Therapeutics Holdings Inc [RANI]. The present Moving Average for the last 50 days of trading for this stock 0.5317, while it was recorded at 0.7108 for the last single week of trading, and 0.9079 for the last 200 days.
Insight into Rani Therapeutics Holdings Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Rani Therapeutics Holdings Inc [RANI] shares currently have an operating margin of -3796.75% and a Gross Margin at 15.33%. Rani Therapeutics Holdings Inc’s Net Margin is presently recorded at -2473.83%.
Rani Therapeutics Holdings Inc (RANI) Capital Structure & Debt Analysis
Rani Therapeutics Holdings Inc (RANI) Efficiency & Liquidity Metrics
Rani Therapeutics Holdings Inc (RANI) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Rani Therapeutics Holdings Inc. (RANI) effectively leverages its workforce, generating an average of -$282761.9 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.54% and a Quick Ratio of 0.54%, indicating strong ability to cover short-term liabilities.
RANI Stock EPS
With the latest financial reports released by the company, Rani Therapeutics Holdings Inc posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.29/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RANI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rani Therapeutics Holdings Inc go to 28.74%.
Rani Therapeutics Holdings Inc [RANI] Institutonal Ownership Details
There are presently around $17.04%, or 21.18%% of RANI stock, in the hands of institutional investors. The top three institutional holders of RANI stocks are: VANGUARD GROUP INC with ownership of 0.71 million shares, which is approximately 2.7265%. NAN FUNG GROUP HOLDINGS LTD, holding 0.49 million shares of the stock with an approximate value of $$1.88 million in RANI stocks shares; and NAN FUNG GROUP HOLDINGS LTD, currently with $$1.7 million in RANI stock with ownership which is approximately 1.7227%.
